170 related articles for article (PubMed ID: 24900631)
1. Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.
Meredith EL; Ksander G; Monovich LG; Papillon JP; Liu Q; Miranda K; Morris P; Rao C; Burgis R; Capparelli M; Hu QY; Singh A; Rigel DF; Jeng AY; Beil M; Fu F; Hu CW; LaSala D
ACS Med Chem Lett; 2013 Dec; 4(12):1203-7. PubMed ID: 24900631
[TBL] [Abstract][Full Text] [Related]
2. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
[TBL] [Abstract][Full Text] [Related]
3. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
[TBL] [Abstract][Full Text] [Related]
4. Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11β-hydroxylase and aldosterone synthase.
Akram M; Patt M; Kaserer T; Temml V; Waratchareeyakul W; Kratschmar DV; Haupenthal J; Hartmann RW; Odermatt A; Schuster D
J Steroid Biochem Mol Biol; 2019 Sep; 192():105358. PubMed ID: 30965118
[TBL] [Abstract][Full Text] [Related]
5. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
Peter M; Dubuis JM; Sippell WG
Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
LaSala D; Shibanaka Y; Jeng AY
Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore Modeling and
Akram M; Waratchareeyakul W; Haupenthal J; Hartmann RW; Schuster D
Front Chem; 2017; 5():104. PubMed ID: 29312923
[TBL] [Abstract][Full Text] [Related]
8. Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1.
Takeda Y; Demura M; Kometani M; Karashima S; Yoneda T; Takeda Y
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982850
[TBL] [Abstract][Full Text] [Related]
9. First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
Hille UE; Zimmer C; Vock CA; Hartmann RW
ACS Med Chem Lett; 2011 Jan; 2(1):2-6. PubMed ID: 24900247
[TBL] [Abstract][Full Text] [Related]
10. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
[TBL] [Abstract][Full Text] [Related]
11. Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study.
Uchida T; Nishimoto K; Fukumura Y; Asahina M; Goto H; Kawano Y; Shimizu F; Tsujimura A; Seki T; Mukai K; Kabe Y; Suematsu M; Gomez-Sanchez CE; Yao T; Horie S; Watada H
Endocr Pathol; 2017 Mar; 28(1):27-35. PubMed ID: 27430645
[TBL] [Abstract][Full Text] [Related]
12. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
Cerny MA; Csengery A; Schmenk J; Frederick K
J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
[TBL] [Abstract][Full Text] [Related]
13. In vitro release of aldosterone and cortisol in human adrenal adenomas correlates to mRNA expression of steroidogenic enzymes for genes CYP11B2 and CYP17.
Enberg U; Farnebo LO; Wedell A; Gröndal S; Thorén M; Grimelius L; Kjellman M; Bäckdahl M; Hamberger B
World J Surg; 2001 Jul; 25(7):957-66. PubMed ID: 11572038
[TBL] [Abstract][Full Text] [Related]
14. Unequal crossing over between CYP11B2 and CYP11B1 causes 11 β -hydroxylase deficiency in a consanguineous family.
Xiong Y; Zeng Z; Liang T; Yang P; Lu Q; Yang J; Zhang J; Fang W; Luo P; Hu Y; Zhang M; Zhou D
J Steroid Biochem Mol Biol; 2023 Oct; 233():106375. PubMed ID: 37572761
[TBL] [Abstract][Full Text] [Related]
15. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects.
Freel EM; Ingram M; Wallace AM; White A; Fraser R; Davies E; Connell JM
Clin Endocrinol (Oxf); 2008 May; 68(5):700-6. PubMed ID: 17980006
[TBL] [Abstract][Full Text] [Related]
16. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
[TBL] [Abstract][Full Text] [Related]
17. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
Müller-Vieira U; Angotti M; Hartmann RW
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
[TBL] [Abstract][Full Text] [Related]
18. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton DP
Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
[TBL] [Abstract][Full Text] [Related]
19. Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.
Brixius-Anderko S; Scott EE
J Biol Chem; 2019 Jan; 294(2):453-460. PubMed ID: 30425102
[TBL] [Abstract][Full Text] [Related]
20. The potential of targeting CYP11B.
Bernhardt R
Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
